<DOC>
	<DOCNO>NCT01962337</DOCNO>
	<brief_summary>This Phase 1 , randomize , double-blind , placebo-controlled study design 3 part assess safety , tolerability , PK single multiple ascend dos FPA008 adult healthy volunteer ( Parts 1 2 ) adult subject active RA ( Part 3 ) .</brief_summary>
	<brief_title>Phase 1 Single Multiple Dose Study FPA008 Healthy Volunteers Rheumatoid Arthritis Subjects</brief_title>
	<detailed_description>Approximately 56 healthy volunteer enrol 1 study center Netherlands Parts 1 2 , approximately 39 subject enrol 6 site Central Eastern Europe Part 3 . Dose escalation Parts 1 2 driven assessment safety profile . Review safety PK parameter may inform decision add cohort intermediate dose level order reach optimal target exposure .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Part 1 2 : Healthy adult male female subject age 2155 year inclusive . Subject must willing remain Clinical Research Unit ( CRU ) minimum 72 hour dose . Part 3 : RA male female subject age 2170 year inclusive Evidence active RA disease Inadequate response biologic nonbiologic DMARDs Subjects require background therapy methotrexate . Parts 1 , 2 3 : BMI &lt; 18 &gt; 32 kg/m2 Clinically significant finding physical exams laboratory test screen and/or baseline Unwilling abstain alcohol 48 hour prior study start , CRU confinement , applicable , 48 hour prior study visit . Unwilling abstain exercise strenuous walk CRU confinement , applicable , 48 hour prior study visit . Parts 1 2 : Use prescription , nonprescription , herbal medication well supplement vitamin within 4 week prior dose , unless approve Investigator . Smoking 10 cigarette , equivalent , per day . Part 3 : Current previous history inflammatory joint disease RA Evidence extraarticular RA disease systemic involvement Currently take medication allow per protocol guideline Any surgical procedure include bone joint surgery within 12 week prior dose Use intraarticular ( IA ) , intramuscular ( IM ) , IV corticosteroids RA Neuropathies neurovasculopathies Concomitant use statin study .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>